Home › Funds › Checkpoint Capital L.P. › RYTM
Checkpoint Capital L.P. position in RYTM
RHYTHM PHARMACEUTICALS INC · Health Care
Checkpoint Capital L.P. reported holding 1,216,574 shares of RYTM (RHYTHM PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$115.8M, representing 26.19% of its reported portfolio and ranking #2 among its reported holdings. Checkpoint Capital L.P. has disclosed RYTM holdings in 12 of the last 12 reported quarters, going back to Q4 2023.
Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR
How Checkpoint Capital L.P.'s RYTM position evolved
Checkpoint Capital L.P. first disclosed a stake in RYTM in Q4 2023 at 730,000 shares (US$33.6M). The position peaked in Q2 2026 at 1,186,000 shares, worth US$131.7M. Across 12 filings, Checkpoint Capital L.P. increased the stake 8 time(s), trimmed it 3 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 1,216,574 shares valued at US$115.8M — an increase of 30,574 shares quarter over quarter.. Notable position changes include a 28% trim in Q3 2024 (shares rose 7% over the following quarter), a 28% trim in Q3 2025 (shares rose 6% over the following quarter), a 30% increase in Q4 2025 (shares fell 19% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2023 | 730.00K | $33.56M | New |
| Q1 2024 | 825.50K | $35.77M | Add |
| Q2 2024 | 922.10K | $37.86M | Add |
| Q3 2024 | 663.38K | $34.75M | Reduce |
| Q4 2024 | 727.98K | $40.75M | Add |
| Q1 2025 | 907.24K | $48.06M | Add |
| Q2 2025 | 1.06M | $66.98M | Add |
| Q3 2025 | 763.71K | $77.13M | Reduce |
| Q4 2025 | 992.20K | $106.21M | Add |
| Q1 2026 | 1.23M | $106.73M | Add |
| Q2 2026 | 1.19M | $131.68M | Reduce |
| Q3 2026 | 1.22M | $115.84M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About RYTM and 13F data
RYTM (RHYTHM PHARMACEUTICALS INC) is a Health Care company. 40 other funds we track also report a position in RYTM — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$740.2M), BAKER BROS. ADVISORS LP (US$622.3M), PERCEPTIVE ADVISORS LLC (US$287.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding RYTM
- RA CAPITAL MANAGEMENT, L.P. 6.67M sh · $740.22M · Q2 2026
- BAKER BROS. ADVISORS LP 5.60M sh · $622.27M · Q2 2026
- PERCEPTIVE ADVISORS LLC 2.59M sh · $287.16M · Q2 2026
- WESTFIELD CAPITAL MANAGEMENT CO LP 2.48M sh · $236.20M · Q3 2026
- Polar Capital Holdings Plc 1.66M sh · $184.71M · Q2 2026
- Siren, L.L.C. 1.09M sh · $103.43M · Q3 2026
- Rock Springs Capital Management LP 692.60K sh · $76.90M · Q2 2026
- Integral Health Asset Management, LLC 550.00K sh · $61.07M · Q2 2026
More on Checkpoint Capital L.P.
FAQ
How long has Checkpoint Capital L.P. held RYTM?
Checkpoint Capital L.P. has disclosed RYTM holdings in 12 of the last 12 reported quarters, going back to Q4 2023.
What is Checkpoint Capital L.P.'s current position in RYTM?
As of Q3 2026, Checkpoint Capital L.P. holds 1.22M shares of RYTM (RHYTHM PHARMACEUTICALS INC), valued at $115.84M, representing 26.19% of its reported portfolio and ranking #2.
Has Checkpoint Capital L.P. been buying or selling RYTM?
In the latest 13F filing (Q3 2026), Checkpoint Capital L.P. increased its position in RYTM. The position peaked in Q2 2026 at 1.19M shares.
Which other funds hold RYTM?
Other major institutional holders of RYTM include RA CAPITAL MANAGEMENT, L.P., BAKER BROS. ADVISORS LP, PERCEPTIVE ADVISORS LLC, among 40 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.